Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Other Non-Current Liabilities (2016 - 2026)

Myriad Genetics has reported Other Non-Current Liabilities over the past 16 years, most recently at $1.7 million for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 96.71% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, down 96.71% year-over-year, with the annual reading at $1.7 million for FY2025, 96.71% down from the prior year.
  • Other Non-Current Liabilities was $1.7 million for Q4 2025 at Myriad Genetics, roughly flat from $1.7 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $51.7 million in Q4 2024 and troughed at $1.7 million in Q3 2025.
  • The 5-year median for Other Non-Current Liabilities is $29.4 million (2021), against an average of $23.3 million.
  • Year-over-year, Other Non-Current Liabilities skyrocketed 780.43% in 2023 and then tumbled 96.71% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $32.1 million in 2021, then surged by 36.76% to $43.9 million in 2022, then increased by 9.57% to $48.1 million in 2023, then grew by 7.48% to $51.7 million in 2024, then tumbled by 96.71% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Other Non-Current Liabilities are $1.7 million (Q4 2025), $1.7 million (Q3 2025), and $1.9 million (Q2 2025).